<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10193454</article-id><article-id pub-id-type="pmcid-ver">PMC10193454.1</article-id><article-id pub-id-type="pmcaid">10193454</article-id><article-id pub-id-type="pmcaiid">10193454</article-id><article-id pub-id-type="manuscript-id">NIHMS1891049</article-id><article-id pub-id-type="pmid">36335834</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109680</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1891049</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1891049</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hallowell</surname><given-names initials="BD">Benjamin D.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chambers</surname><given-names initials="LC">Laura C.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samuels</surname><given-names initials="EA">Elizabeth A.</given-names></name><xref rid="A3" ref-type="aff">c</xref><xref rid="A4" ref-type="aff">d</xref><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bratberg</surname><given-names initials="J">Jeffrey</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McDonald</surname><given-names initials="J">James</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nitenson</surname><given-names initials="A">Adam</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onyejekwe</surname><given-names initials="C">Collette</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beaudoin</surname><given-names initials="FL">Francesca L.</given-names></name><xref rid="A3" ref-type="aff">c</xref><xref rid="A4" ref-type="aff">d</xref></contrib></contrib-group><aff id="A1"><label>a</label>Substance Use Epidemiology Program, Rhode Island Department of Health, Providence, RI, USA</aff><aff id="A2"><label>b</label>Division of Infectious Diseases, The Miriam Hospital, Providence, RI, USA</aff><aff id="A3"><label>c</label>Department of Epidemiology, Brown University, Providence, RI, USA</aff><aff id="A4"><label>d</label>Department of Emergency Medicine, Brown University, Providence, RI, USA</aff><aff id="A5"><label>e</label>Drug Overdose Prevention Program, Rhode Island Department of Health, Providence, RI, USA</aff><aff id="A6"><label>f</label>Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, RI, USA</aff><aff id="A7"><label>g</label>Prescription Drug Monitoring Program, Rhode Island Department of Health, Providence, RI, USA</aff><author-notes><corresp id="CR1"><label>*</label>Correspondence to: Center for Health Data and Analysis, Rhode Island Department of Health, 3 Capital Hill, Providence, RI 02908, USA. <email>Benjamin.Hallowell@health.ri.gov</email> (B.D. Hallowell).</corresp><fn fn-type="COI-statement" id="FN2"><p id="P27">Conflicts of interest</p><p id="P28">All authors declare that they have no conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2022</year></pub-date><volume>241</volume><issue-id pub-id-type="pmc-issue-id">436036</issue-id><fpage>109680</fpage><lpage>109680</lpage><pub-history><event event-type="nihms-submitted"><date><day>14</day><month>04</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1891049.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and Aims:</title><p id="P1">Partial opioid agonist medications for opioid use disorder reduce mortality and morbidity, however long-term retention in treatment is challenging. The objective of this study was to identify patient and prescription characteristics associated with long-term buprenorphine treatment retention.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We used data from the Rhode Island prescription drug monitoring program to identify residents who initiated buprenorphine treatment and determine if they were retained in long-term buprenorphine treatment 12-months after treatment initiation. Multivariable logistic regression models were used to identify sociodemographic and prescription characteristics associated with long-term buprenorphine retention.</p></sec><sec id="S3"><title>Findings:</title><p id="P3">During the study period 4898 unique Rhode Island residents initiated buprenorphine treatment, of whom 37.8 % were retained in treatment at 12-months. Demographic factors associated with a higher odds of long-term buprenorphine retention included older age, female sex, Medicaid insurance (vs private), and living closer to the pharmacy where the prescription was filled. Individuals who were prescribed the tablet formulation (aOR: 0.82 [95 % CI 0.72, 0.93]) or received a non-buprenorphine opioid during the follow-up window (aOR: 37 [95 % CI 0.31, 0.44]) had lower odds of long-term treatment at 12-months. Individuals who received at least one day of overlapping benzodiazepine and buprenorphine prescriptions (aOR: 2.00 [95 % CI 1.70, 2.34]) and those given a longer days supply (aOR: 1.26 [95 % CI 1.01, 1.56]) had higher odds of long-term treatment at 12-months. Findings were similar for treatment retention at 6-months in sensitivity analyses.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">These findings highlight several modifiable prescribing practices associated with long-term buprenorphine retention, suggesting that clinicians and public health practitioners can help remove barriers to long-term retention.</p></sec></abstract><kwd-group><kwd>Buprenorphine</kwd><kwd>Opioid use disorder</kwd><kwd>Opioid</kwd><kwd>Retention</kwd><kwd>Healthcare</kwd><kwd>Prescription drug monitoring</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>